WG
CCCC icon

Winton Group’s C4 Therapeutics CCCC Stock Holding History

Winton Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.8K Sell
11,100
-13,600
-55% -$46.5K ﹤0.01% 1123
2026
Q1 		$65K Buy
+24,700
New +$58.2K ﹤0.01% 1059

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Winton Group's CCCC Position: Q2 2026 in Review

Winton Group reduced its C4 Therapeutics (CCCC) stake by 55% in Q2 2026, selling an estimated $46.5K and leaving 11,100 shares worth $51.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1123.

Winton Group first reported a position in CCCC in Q1 2026 and has held it in 2 quarters since. The position peaked at $65K in Q1 2026. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Winton Group held 11,100 shares of C4 Therapeutics worth $51.8K as of Q2 2026.
  • Winton Group sold 13,600 C4 Therapeutics shares in Q2 2026, an estimated $46.5K.
  • C4 Therapeutics made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1123 holding.
  • Winton Group first reported a position in C4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Winton Group's C4 Therapeutics position peaked at $65K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.